Curcumin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Curcumin for Health & Longevity

Created on 09/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Turmeric's yellow pigment, with a mixed evidence base. Clearest human results are about how people feel: less knee arthritis pain and better function, about as well as common anti-inflammatory drugs, with fewer stomach complaints. Smaller consistent changes in blood fats, blood sugar and inflammation. Memory and blood pressure conflict. Nothing in humans touches lifespan. Liver injury documented with concentrated products. (Full Review)

Protocol

Standard dose range
1,000–1,500 mg daily
The range integrative practitioners typically settle at for a standardized 95% curcuminoid extract in joint and inflammatory indications; most trials used 500–2,000 mg of curcuminoids daily.
Absorption-enhanced formulations
The dominant approach
Phospholipid (Meriva, 500–1,000 mg daily), colloidal-dispersion (Theracurmin, 90–180 mg daily) and turmeric-oil (BCM-95, 500–1,000 mg daily) products dominate the positive trial literature.
Half-life and dose splitting
Two or three daily doses
Splitting is standard for unformulated products, whose plasma half-life is roughly 1–2 hours against up to 6–8 hours for phospholipid forms; dosing is anchored to meals rather than the clock.
Time to effect
Joint pain
4–8 weeks
Responses typically emerge here and are usually assessed at 12 weeks.
Lipid, glycemic and inflammatory changes
At least 8 weeks
Markers are repeated at 12 weeks, the point by which pooled trial data show effects emerging.
Memory and attention
18 months
The cognitive trial ran 18 months, in adults aged 51–84.

Benefits

Contraindications
  • Pregnancy and lactation
  • Gallstones, biliary obstruction, or cholangitis
  • Active or recent drug-induced liver injury, or alanine aminotransferase above three times the upper limit of normal
  • Recurrent calcium-oxalate kidney stones with 24-hour urinary oxalate above 40 mg
  • Scheduled surgery within 14 days, or any invasive procedure with meaningful bleeding risk
  • Solid-organ transplant recipients on tacrolimus, ciclosporin or sirolimus
  • Tamoxifen or taxane chemotherapy, unless cleared by the treating oncologist
  • Diagnosed iron-deficiency anaemia (haemoglobin below 12 g/dL in women, 13 g/dL in men) until corrected
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)
  • Sulfasalazine and other P-glycoprotein substrates (digoxin, talinolol, fexofenadine)
  • Antidiabetic drugs (metformin, sulfonylureas, insulin)
  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin)
  • Over-the-counter antacids and acid-suppressing drugs (omeprazole, famotidine, calcium carbonate)
  • Iron supplements (ferrous sulphate, ferrous bisglycinate)
  • Piperine-containing products (BioPerine, black pepper extract)
  • Other hepatotoxic botanicals (green tea extract, ashwagandha, red yeast rice)
  • Supplements with additive anti-inflammatory or antiplatelet effects (fish oil, garlic extract, ginkgo, boswellia)
  • Supplements with additive glucose-lowering effects (berberine, chromium, alpha-lipoic acid, cinnamon extract)
  • Radiotherapy and cytotoxic chemotherapy
    •

Risk & Side Effects

  • High: Gastrointestinal intolerance
    •
  • Medium: Drug-induced liver injury; increased urinary oxalate and kidney-stone risk
  • Low: Interference with drug metabolism and transport; bleeding risk with antiplatelet or anticoagulant therapy; impaired iron absorption and iron status; lead and adulterant contamination of turmeric products; gallbladder contraction
  • Speculative: Reduced sperm motility and fertility at high doses; blunting of training adaptations from exercise

Monitoring

Marker Target Why
Alanine aminotransferase <25 U/L (men), <20 U/L (women) Earliest signal of the main serious harm
Aspartate aminotransferase <25 U/L Confirms a liver-cell injury pattern alongside alanine aminotransferase
Alkaline phosphatase and total bilirubin Alkaline phosphatase 40–100 U/L; bilirubin 0.3–1.0 mg/dL Reported turmeric liver injury is cholestatic or mixed in part of the case literature, so these can move before or with the transaminases
High-sensitivity C-reactive protein <1.0 mg/L The primary marker curcumin is expected to move; defines whether there is headroom to respond
Fasting glucose and glycated haemoglobin Glucose 75–90 mg/dL; glycated haemoglobin 4.8–5.4% Tracks the glycemic benefit, which is the largest in people starting high
Fasting lipid panel Triglycerides <80 mg/dL; low-density lipoprotein cholesterol individualised to overall cardiovascular risk Triglycerides and low-density lipoprotein cholesterol are the two lipid endpoints with clinically meaningful pooled changes
Ferritin 50–150 ng/mL (men and postmenopausal women); 40–100 ng/mL (menstruating women) Detects the iron depletion suggested by rodent chelation data
Haemoglobin and complete blood count Haemoglobin 14–16 g/dL (men), 13.5–15.5 g/dL (women) Confirms whether any ferritin fall has progressed to anaemia
24-hour urinary oxalate (stone formers only) <30 mg/24 h Turmeric measurably raises oxalate excretion, the main driver of calcium-oxalate stones

Cadence: Baseline testing before the first dose; liver panel repeated at 6–8 weeks, again at 6 months, then annually. Inflammatory, lipid and glycemic markers at 12 weeks, then every 6–12 months. Iron studies at 6 and 12 months.

Qualitative Assessment

  • Subjective joint pain score — no established target; change from the individual's own baseline on a 0–10 scale, assessed at 12 weeks
  • Morning joint stiffness — duration in minutes on waking, recorded weekly
  • Joint pain during a defined activity, such as stairs or a specific lift, rated 0–10
  • Reliance on anti-inflammatory drugs — tablets per week, the most sensible real-world success measure
  • Post-exercise soreness at 24 and 48 hours after a hard session
  • Digestive comfort — bloating, stool consistency and reflux, which flag the commonest side effect
  • Mood and motivation, noting that trial effects took 8–12 weeks to appear
  • Energy and exercise tolerance, which fall early if iron stores are being depleted
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.